2Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metaboliam from fatty acid oxidation to glucose oxidation by inhibiting mitochondral long- chain 3 - ketoacyl coenzyme a thiolase[J]. Circ Res, 2000,86:580 - 588.
3Lopaschuk GD, Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart (abstr)[J] .J Mol Cell Cardiol, 1998,30:A112.
4Weintraub WS, Stein B, Kosinski A, et al. Outcome of coronary bypass surgery versue coronary angioplasty in diabetic patients with multivessel coronary artery disease[J] .J Am Coll Cardiol, 1998,31 : 10 - 19.
5Allibardi S, Oaierchia SL, Margonato V, et al. Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts [ J ].Cardiovasc Drugs Ther, 1998,12:543 - 549.
6Lu C,Dabrwski P,Fragasso G, et al .Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease[J].Am J Cardlol, 1998,82:8989 - 8901.
7Szwed H, Sadowski Z, Pachocki R, et al. Efficacy and safety of trimetazidine in patients with persistent stable angina pectoris under beta-blocker therapy:TRLMPOL Ⅱ multicentre study[J]. Eur Heart J,1999,20: Abstract No.2516.
8Szwed H, Sadowski X, Pactocki R, et al. Anti - ischemic efficacy and tolerability of trimetazidine in elderly patients with angina pectoris[J].Clin Drugs Invest, 2000,19: L1 - 98.
二级参考文献1
1Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999
